Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) has received an average rating of “Buy” from the fourteen analysts that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $377.20.
A number of equities analysts have recently issued reports on the company. Bank of America increased their price target on Krystal Biotech from $392.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, September 21st. Weiss Ratings lowered Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, October 9th. William Blair upgraded Krystal Biotech to a “strong-buy” rating in a report on Wednesday, September 23rd. Royal Bank Of Canada started coverage on shares of Krystal Biotech in a research note on Friday, August 14th. They issued an “outperform” rating and a $400.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $361.00 target price on shares of Krystal Biotech in a report on Thursday, October 15th.
View Our Latest Analysis on KRYS
Krystal Biotech Stock Up 1.2%
Shares of NASDAQ:KRYS opened at $320.25 on Tuesday. Krystal Biotech has a 52-week low of $183.03 and a 52-week high of $382.54. The stock has a market cap of $9.48 billion, a P/E ratio of 39.67 and a beta of 0.50. The business’s 50 day moving average is $340.18 and its 200 day moving average is $324.12.
Krystal Biotech (NASDAQ:KRYS – Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The company reported $1.79 EPS for the quarter, topping the consensus estimate of $1.70 by $0.09. The company had revenue of $119.22 million for the quarter, compared to the consensus estimate of $120.93 million. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. On average, sell-side analysts anticipate that Krystal Biotech will post 7.40 EPS for the current fiscal year.
Insider Activity
In other news, Director Dino A. Rossi sold 25,000 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the transaction, the director directly owned 50,000 shares in the company, valued at approximately $16,456,000. This trade represents a 33.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the transaction, the insider directly owned 1,302,145 shares in the company, valued at approximately $467,886,741.40. The trade was a 1.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 13.10% of the company’s stock.
Hedge Funds Weigh In On Krystal Biotech
A number of large investors have recently bought and sold shares of KRYS. BlackRock Inc. bought a new position in shares of Krystal Biotech during the 2nd quarter worth approximately $1,554,113,000. William Blair Investment Management LLC acquired a new stake in Krystal Biotech in the second quarter valued at approximately $211,909,000. Jupiter Topco LLC acquired a new stake in Krystal Biotech in the second quarter valued at approximately $95,387,000. Bank of America Corp DE purchased a new position in Krystal Biotech in the second quarter worth $95,308,000. Finally, Bank of New York Mellon Corp purchased a new position in Krystal Biotech in the second quarter worth $60,809,000. Institutional investors own 86.29% of the company’s stock.
About Krystal Biotech
Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company’s platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.
Krystal’s lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.
See Also
- Five stocks we like better than Krystal Biotech
- D-Wave Stock Has 2 New Reasons for Investors to Pay Attention
- Amprius Technologies’ Next Big Rally Could Be Taking Shape
- 4 Stocks With Demand So Sticky That the AI Sell-Off Barely Touched Them at All
- Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
